Malvina Svilenova Todorova

Dr. Malvina Svilenova Todorova

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2026 in Diabetology
Verified
Journal Article
Open access
PDF file
VTVictoria Tsvetanova Tsvetkova
Victoria Tsvetanova Tsvetkova
MTMalvina Svilenova Todorova
Malvina Svilenova Todorova
MAMilena Atanasova
Milena Atanasova
IGIrena Gencheva
Irena Gencheva
KTKatya Nikolova Todorova
Katya Nikolova Todorova
Aims/hypothesis: Hypoxia and oxidative stress have been implicated in both metabolic syndrome and COVID-19-associated dysglycaemia, yet it remains unclear whether shared or distinct mechanisms underlie β-cell dysfunction across these conditions. We investigated hypoxia- and oxidative stress-related pathways in relation to β-cell function during acute COVID-19, post-COVID metabolic states, and COVID-negative metabolic syndrome. Methods: In this prospective observational study, 100 adults were stratified into three groups: active COVID-19 (n = 32), post-COVID with newly diagnosed carbohydrate metabolism disorders (n = 35), and COVID-negative individuals with metabolic syndrome (n = 33). Circulating markers of hypoxia (HIF-1α), oxidative stress (8-epi-prostaglandin F2α), and antioxidant response (NFE2L2) were measured alongside α- and β-cell functional markers, including C-peptide, proinsulin, glucagon, and derived indices of β-cell processing and secretory efficiency. Non-parametric statistical analyses were applied. Results: Circulating HIF-1α levels differed significantly across study groups (p < 0.001), with the highest concentrations observed during active COVID-19, intermediate levels in COVID-negative individuals with metabolic syndrome, and the lowest levels in the post-COVID group. In contrast, oxidative stress, assessed by 8-epi-prostaglandin F2α, differed significantly across groups (p < 0.001), increasing from acute COVID-19 to post-COVID and reaching the highest levels in metabolic syndrome; however, the difference between the post-COVID and metabolic syndrome groups did not remain significant after correction for multiple testing. NFE2L2 concentrations did not differ significantly between groups. Marked β-cell dysfunction was observed predominantly in COVID-negative individuals with metabolic syndrome, characterized by reduced C-peptide levels, elevated glucagon concentrations, increased proinsulin/C-peptide ratios, and reduced C-peptide/glucose ratios (all overall group comparisons p < 0.001). In contrast, β-cell secretory indices were relatively preserved during acute and post-COVID states despite pronounced alterations in hypoxia and oxidative stress markers. Conclusions/interpretation: Hypoxia- and oxidative stress-related pathways exhibit distinct, context-dependent patterns across acute COVID-19, post-COVID dysglycaemia, and metabolic syndrome. Acute COVID-19 is characterized by pronounced hypoxia signalling with relative preservation of β-cell function, whereas chronic metabolic syndrome is associated with sustained oxidative stress and impaired β-cell processing and secretory efficiency. These findings suggest that diabetes-related β-cell dysfunction is more closely associated with chronic oxidative and metabolic stress than with transient infection-related hypoxia during SARS-CoV-2 infection.

5 February 2025 in Journal of Biomedical and Clinical Research
Verified
Journal Article
Open access
PDF file
MTMalvina Svilenova Todorova
Malvina Svilenova Todorova
KTKatya Todorova
Katya Todorova
With the outbreak of the COVID-19 pandemic, the scientific community has directed its attention towards studying the impact of the causative agent, SARS-CoV-2, on the endocrine system. It has been proven that the virus exhibits organotropism towards the cortex of the adrenal glands, causing tissue damage and hormonal dysfunction. The aim of this exposition is to address the question of whether SARS-CoV-2 causes disruptions in the hormonal regulation of glucocorticoid hormones. Based on a thorough review of the current literature, it is suggested that the virus could potentially directly damage the hypothalamus, leading to a disruption in the regulation of the hypothalamic-pituitary-adrenal axis. The decrease in cortisol secretion is a secondary effect. As a result, there is a loss of stress-induced cortisol elevation due to the inflammatory process and an increased risk of adrenal crisis. On the other hand, inflammatory cytokines synthesized during the inflammatory process could stimulate cortisol secretion through an ACTH-independent mechanism. The magnitude of the biological response is influenced by the newly emerged resistance of cortisol receptors, disturbances in intracellular cortisol signaling, and dysregulation between ACTH and cortisol secretion. The detailed study of functional changes in cortisol secretion in response to SARS-CoV-2-associated inflammation provides a new horizon for scientific research following recovery from COVID-19.

13 March 2026 in COVID
Verified
Journal Article
Open access
PDF file
MTMalvina Svilenova Todorova
Malvina Svilenova Todorova
VTVictoria Tsvetanova Tsvetkova
Victoria Tsvetanova Tsvetkova
MAMilena Atanasova
Milena Atanasova
ARAdelaida Ruseva
Adelaida Ruseva
KTKatya Nikolova Todorova
Katya Nikolova Todorova
Coronavirus disease 2019 (COVID-19) is associated with systemic inflammation and immune dysregulation, potentially affecting hypothalamic–pituitary–adrenal (HPA) axis function and glucocorticoid signaling. However, the dynamics and clinical relevance of these alterations across different disease phases remain insufficiently defined. In this cross-sectional observational study, 101 participants were divided into three groups: patients with active COVID-19 (n = 33), individuals ≥ 6 months post-COVID-19 (n = 35), and a reference group of healthy individuals (n = 33). Serum cortisol, circulating glucocorticoid receptor alpha (GRα), and selected cytokines were measured. Statistical analysis included parametric and non-parametric tests, multivariable generalized linear models adjusted for age and sex, correlation analysis, and receiver operating characteristic (ROC) analysis. Lower serum cortisol levels were observed in approximately two-thirds of patients during the acute phase. Circulating GRα concentrations demonstrated a significant gradient across groups, with the lowest levels in active infection and partial restoration post-COVID. Active COVID-19 status remained independently associated with reduced GRα levels after adjustment for age and sex. The cytokine profile, including interleukin-17A (IL-17A), tumor necrosis factor-alpha (TNF-α), and interleukin-10 (IL-10), provided a mechanistic context for inflammation-associated modulation of glucocorticoid signaling, most evident during acute infection. Significant correlations between cortisol, GRα, and inflammatory mediators were observed only in this phase. ROC analysis demonstrated a high degree of statistical separation between active COVID-19 and healthy individuals (AUC 0.942; 95% CI: 0.878–1.000). Given the predefined group structure and modest sample size, these findings should be considered exploratory. Overall, the results support the presence of dynamic and potentially reversible immune–endocrine dysregulation during and after SARS-CoV-2 infection. Further validation in larger prospective cohorts is required.

24 September 2026 in Endocrinologia
Verified
Journal Article
Open access
PDF file
MTMalvina Svilenova Todorova
Malvina Svilenova Todorova
KTKatya Nikolova Todorova
Katya Nikolova Todorova
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an established therapeutic class for the management of type 2 diabetes mellitus and obesity. Their increasing use among women of reproductive age has raised important concerns regarding their potential impact on fertility, preconception care, and safety during pregnancy. Current evidence suggests that GLP-1RAs may exert beneficial effects on ovulatory function, menstrual regularity, and the inflammatory milieu, particularly in women with insulin resistance and hyperandrogenism. Potential effects on endometrial function, implantation, and maternal–fetal immune tolerance have also been discussed. Nevertheless, the available evidence regarding exposure during pregnancy remains limited. Findings from animal studies have raised concerns about fetal development, particularly with respect to skeletal ossification, skin development, and neurogenesis, whereas observational studies in humans appear somewhat reassuring regarding the risk of major congenital malformations, although they do not allow for definitive safety conclusions. Consequently, GLP-1RAs are not recommended during pregnancy, and women with reproductive intentions should receive individualized preconception counseling and guidance regarding an appropriate treatment discontinuation period prior to conception.

23 June 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
VTVictoria Tsvetanova Tsvetkova
Victoria Tsvetanova Tsvetkova
MTMalvina Svilenova Todorova
Malvina Svilenova Todorova
MAMilena Atanasova
Milena Atanasova
IGIrena Gencheva
Irena Gencheva
KTKatya Nikolova Todorova
Katya Nikolova Todorova
Background: SARS-CoV-2 infection has been associated with metabolic disturbances and endocrine alterations, including effects on pancreatic β-cell function and thyroid hormone regulation. However, the relationship between thyroid function and β-cell compensatory capacity in the post-COVID state remains unclear. Methods: In this cross-sectional study, we evaluated β-cell compensation (HOMA-B/HOMA-IR) and thyroid parameters in three groups: patients with active COVID-19, individuals with post-COVID metabolic disturbances, and a COVID-negative metabolic syndrome reference group. Thyroid status was assessed using both comprehensive clinical classification and biochemical criteria. Associations between thyroid hormones and β-cell function were analyzed using Spearman correlation. Results: β-cell compensatory capacity differed significantly across groups, with the lowest values observed during active COVID-19 and intermediate impairment in the post-COVID cohort compared with the metabolic syndrome group. FT3 concentrations and the FT3/FT4 ratio were significantly reduced during active infection and were positively associated with β-cell compensation in the post-COVID group (ρ = 0.421, p = 0.018 and ρ = 0.382, p = 0.031, respectively). Although thyroid dysfunction appeared more prevalent in the post-COVID cohort when defined by overall clinical classification, no significant differences were observed when thyroid status was evaluated based solely on biochemical criteria, excluding clinical history and euthyroid sick syndrome. Conclusions: Post-COVID metabolic disturbances are characterized by impaired β-cell compensatory capacity and alterations in peripheral thyroid hormone dynamics. The apparent increase in thyroid dysfunction is largely driven by pre-existing thyroid disease and non-thyroidal illness effects rather than intrinsic thyroid pathology. These findings are consistent with the hypothesis of a potential post-COVID immunometabolic phenotype involving both pancreatic and thyroid-related mechanisms.